238 related articles for article (PubMed ID: 9429136)
1. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations.
Fanin M; Duggan DJ; Mostacciuolo ML; Martinello F; Freda MP; Sorarù G; Trevisan CP; Hoffman EP; Angelini C
J Med Genet; 1997 Dec; 34(12):973-7. PubMed ID: 9429136
[TBL] [Abstract][Full Text] [Related]
2. Autosomal recessive muscular dystrophy and mutations of the sarcoglycan complex.
Duggan DJ; Hoffman EP
Neuromuscul Disord; 1996 Dec; 6(6):475-82. PubMed ID: 9027858
[TBL] [Abstract][Full Text] [Related]
3. Genomic screening for beta-sarcoglycan gene mutations: missense mutations may cause severe limb-girdle muscular dystrophy type 2E (LGMD 2E).
Bönnemann CG; Passos-Bueno MR; McNally EM; Vainzof M; de Sá Moreira E; Marie SK; Pavanello RC; Noguchi S; Ozawa E; Zatz M; Kunkel LM
Hum Mol Genet; 1996 Dec; 5(12):1953-61. PubMed ID: 8968749
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the sarcoglycan genes in patients with myopathy.
Duggan DJ; Gorospe JR; Fanin M; Hoffman EP; Angelini C
N Engl J Med; 1997 Feb; 336(9):618-24. PubMed ID: 9032047
[TBL] [Abstract][Full Text] [Related]
5. Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb-girdle muscular dystrophy in the Brazilian population.
Vainzof M; Passos-Bueno MR; Pavanello RC; Marie SK; Oliveira AS; Zatz M
J Neurol Sci; 1999 Mar; 164(1):44-9. PubMed ID: 10385046
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the delta-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2).
Duggan DJ; Manchester D; Stears KP; Mathews DJ; Hart C; Hoffman EP
Neurogenetics; 1997 May; 1(1):49-58. PubMed ID: 10735275
[TBL] [Abstract][Full Text] [Related]
7. Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy.
McNally EM; Duggan D; Gorospe JR; Bönnemann CG; Fanin M; Pegoraro E; Lidov HG; Noguchi S; Ozawa E; Finkel RS; Cruse RP; Angelini C; Kunkel LM; Hoffman EP
Hum Mol Genet; 1996 Nov; 5(11):1841-7. PubMed ID: 8923014
[TBL] [Abstract][Full Text] [Related]
8. [The frequency of patients with adhalin deficiency in a muscular dystrophy patient population].
Hayashi YK; Arahata K
Nihon Rinsho; 1997 Dec; 55(12):3165-8. PubMed ID: 9436429
[TBL] [Abstract][Full Text] [Related]
9. Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation.
McNally EM; Passos-Bueno MR; Bönnemann CG; Vainzof M; de Sá Moreira E; Lidov HG; Othmane KB; Denton PH; Vance JM; Zatz M; Kunkel LM
Am J Hum Genet; 1996 Nov; 59(5):1040-7. PubMed ID: 8900232
[TBL] [Abstract][Full Text] [Related]
10. Phenotype and sarcoglycan expression in Tunisian LGMD 2C patients sharing the same del521-T mutation.
Kefi M; Amouri R; Driss A; Ben Hamida C; Ben Hamida M; Kunkel LM; Hentati F
Neuromuscul Disord; 2003 Dec; 13(10):779-87. PubMed ID: 14678800
[TBL] [Abstract][Full Text] [Related]
11. Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity.
Dressman D; Araishi K; Imamura M; Sasaoka T; Liu LA; Engvall E; Hoffman EP
Hum Gene Ther; 2002 Sep; 13(13):1631-46. PubMed ID: 12228018
[TBL] [Abstract][Full Text] [Related]
12. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations.
Barresi R; Di Blasi C; Negri T; Brugnoni R; Vitali A; Felisari G; Salandi A; Daniel S; Cornelio F; Morandi L; Mora M
J Med Genet; 2000 Feb; 37(2):102-7. PubMed ID: 10662809
[TBL] [Abstract][Full Text] [Related]
13. Private beta- and gamma-sarcoglycan gene mutations: evidence of a founder effect in Northern Italy.
Fanin M; Hoffman EP; Angelini C; Pegoraro E
Hum Mutat; 2000; 16(1):13-7. PubMed ID: 10874299
[TBL] [Abstract][Full Text] [Related]
14. A first missense mutation in the delta sarcoglycan gene associated with a severe phenotype and frequency of limb-girdle muscular dystrophy type 2F (LGMD2F) in Brazilian sarcoglycanopathies.
Moreira ES; Vainzof M; Marie SK; Nigro V; Zatz M; Passos-Bueno MR
J Med Genet; 1998 Nov; 35(11):951-3. PubMed ID: 9832045
[TBL] [Abstract][Full Text] [Related]
15. The clinical spectrum of sarcoglycanopathies.
Angelini C; Fanin M; Freda MP; Duggan DJ; Siciliano G; Hoffman EP
Neurology; 1999 Jan; 52(1):176-9. PubMed ID: 9921870
[TBL] [Abstract][Full Text] [Related]
16. Molecular and genetic characterization of sarcospan: insights into sarcoglycan-sarcospan interactions.
Crosbie RH; Lim LE; Moore SA; Hirano M; Hays AP; Maybaum SW; Collin H; Dovico SA; Stolle CA; Fardeau M; Tomé FM; Campbell KP
Hum Mol Genet; 2000 Aug; 9(13):2019-27. PubMed ID: 10942431
[TBL] [Abstract][Full Text] [Related]
17. Characterization of delta-sarcoglycan, a novel component of the oligomeric sarcoglycan complex involved in limb-girdle muscular dystrophy.
Jung D; Duclos F; Apostol B; Straub V; Lee JC; Allamand V; Venzke DP; Sunada Y; Moomaw CR; Leveille CJ; Slaughter CA; Crawford TO; McPherson JD; Campbell KP
J Biol Chem; 1996 Dec; 271(50):32321-9. PubMed ID: 8943294
[TBL] [Abstract][Full Text] [Related]
18. alpha-Sarcoglycan (adhalin) deficiency: complete deficiency patients are 5% of childhood-onset dystrophin-normal muscular dystrophy and most partial deficiency patients do not have gene mutations.
Duggan DJ; Fanin M; Pegoraro E; Angelini C; Hoffman EP
J Neurol Sci; 1996 Sep; 140(1-2):30-9. PubMed ID: 8866424
[TBL] [Abstract][Full Text] [Related]
19. LGMD 2E in Tunisia is caused by a homozygous missense mutation in beta-sarcoglycan exon 3.
Bönnemann CG; Wong J; Ben Hamida C; Hamida MB; Hentati F; Kunkel LM
Neuromuscul Disord; 1998 May; 8(3-4):193-7. PubMed ID: 9631401
[TBL] [Abstract][Full Text] [Related]
20. Primary gamma-sarcoglycanopathy (LGMD 2C): broadening of the mutational spectrum guided by the immunohistochemical profile.
Bönnemann CG; Wong J; Jones KJ; Lidov HG; Feener CA; Shapiro F; Darras BT; Kunkel LM; North KN
Neuromuscul Disord; 2002 Mar; 12(3):273-80. PubMed ID: 11801399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
